Attending to modifiable risk factors is an important treatment target in patients with atrial fibrillation treated with anticoagulants to reduce thromboembolic and bleeding events.
Detecting previously undiagnosed, asymptomatic AF may help to prevent future thromboembolic events and the onset of symptoms, and may reduce AF-related morbidity and hospitalizations.
In order to revise the guidelines, the Task Force reviewed clinical trials presented at the annual scientific meetings of the ACC, AHA, HRS, and European Society of Cardiology in addition to other peer-reviewed, published data.
There are limited published data on the efficacy and safety of direct-acting oral anticoagulants (DOACs) in patients with end-stage renal disease (ESRD) on dialysis and atrial fibrillation.
Updated guidelines also emphasize weight loss for overweight, obese patients with atrial fibrillation.
Findings of early trials based on epicardial fat pad injections during cardiac surgery.
Baseline serum 25(OH)D level was not predictive of long-term incident atrial fibrillation risk.
Those who do see a cardiologist are more likely to fill anticoagulant prescription and have reduced risk for stroke.
Probands of African or Hispanic/Latino descent with early-onset atrial fibrillation are more likely than European Americans to have a first-degree relative with AF.
Patients with atrial fibrillation who have ≥1 non-sex CHA2DS2VASc stroke risk factor should receive oral anticoagulation as antithrombotic therapy.
